Immix Biopharma, INC Form 4 insider transactions

Director Jason Hsu reports acquisition of stock options and details beneficial ownership of Immix Biopharma shares through direct and indirect holdings.

Immix Biopharma's CEO and Chairman, Ilya Rachman, acquired 340,000 stock options at an exercise price of $2.04 on June 11, 2024, according to a Form 4 filing.

Director Jane Buchan reports the acquisition of stock options in Immix Biopharma, Inc.

Director Carey Ng reports the acquisition of stock options and disposal of common stock, along with indirect ownership details.

Director Helen C. Adams reports acquisition of stock options in Immix Biopharma, Inc.

CFO Gabriel Morris reports the acquisition of stock options and changes in beneficial ownership of Immix Biopharma, Inc. shares.

Immix Biopharma's CEO and Chairman, Ilya Rachman, purchased 2,600 shares of common stock at $2.13 per share on June 7, 2024.

Gabriel Morris, CFO of Immix Biopharma, recently purchased 2,500 shares of the company's common stock at a price of $2.1192 per share.

CFO of Immix Biopharma, Gabriel Morris, reports the acquisition of 3,300 shares of common stock at $1.8099 per share.

Ilya Rachman, CEO and Chairman of Immix Biopharma, Inc., purchased 3,300 shares of common stock at $1.8091 per share on June 4, 2024.

Director Helen C. Adams reports acquiring shares of Immix Biopharma, Inc. following the merger with Nexcella, Inc.

Ilya Rachman, CEO and Chairman of Immix Biopharma, reports acquiring 218,359 shares of common stock due to a merger with Nexcella, Inc.

Director Jason Hsu reports stock option grants and beneficial ownership of Immix Biopharma shares, including holdings through VERITAS LIBERABIT VOS, LLC and Signature Collection Properties, LLC.

Director Jane Buchan reports acquisition of Immix Biopharma stock and options related to the merger with Nexcella, Inc.

Director Magda Marquet reports acquisition of Immix Biopharma shares, including those received in exchange for Nexcella, Inc. stock following the merger.

Director Carey Ng reports a transaction involving Immix Biopharma stock options and shares.

CFO Gabriel Morris reports changes in beneficial ownership of Immix Biopharma stock following the merger with Nexcella, Inc.

CFO of Immix Biopharma, Gabriel Morris, reports the purchase of 4,500 shares of common stock at $2.2315 per share.

Immix Biopharma's CEO and Chairman, Ilya Rachman, purchased 4,300 shares of common stock at a price of $2.2465 per share on May 14, 2024.